期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
贞芪扶正胶囊辅助大肠癌术后化疗临床观察 被引量:11
1
作者 冯滢滢 李军 +3 位作者 刘泉龙 张云静 赵克 丁建华 《北京中医药》 2015年第10期810-812,共3页
目的观察贞芪扶正胶囊在结直肠癌患者术后配合m FOLFOX6方案辅助化疗的疗效和不良反应。方法将52例仅行常规辅助化疗患者作为对照组与50例加用贞芪扶正胶囊辅助化疗患者作为观察组进行回顾性分析,比较2组生活质量状况、骨髓毒性、细胞... 目的观察贞芪扶正胶囊在结直肠癌患者术后配合m FOLFOX6方案辅助化疗的疗效和不良反应。方法将52例仅行常规辅助化疗患者作为对照组与50例加用贞芪扶正胶囊辅助化疗患者作为观察组进行回顾性分析,比较2组生活质量状况、骨髓毒性、细胞免疫功能和不良反应发生情况。结果观察组卡氏评分(KPS)提高和稳定率为76%,高于对照组的55.8%,差异有统计学意义(P<0.05);观察组骨髓抑制率44%,对照组为65%,2组比较差异有统计学意义(P<0.05);2组NK阳性细胞百分率与治疗前比较差异无统计学意义(P>0.05),但治疗后2组间差异有统计学意义(P<0.05);观察组消化道反应、神经毒性、肝脏毒性、肾脏毒性均轻于对照组,发生乏力病例数少于对照组,但差异无统计学意义(P>0.05)。结论化疗中加用贞芪扶正胶囊可提高患者术后的免疫力,减轻不良反应,改善生活质量,可作为化疗的常规辅助用药。 展开更多
关键词 贞芪扶正胶囊 大肠癌:化疗 辅助用药
下载PDF
晚期大肠癌化疗护理 被引量:1
2
作者 张明珍 田丰霞 《中国中医药现代远程教育》 2012年第3期107-107,共1页
大肠癌是世界范围内最常见的恶性肿瘤之一,我国近年来发病率有升高趋势。局部复发和远处转移是大肠癌治疗失败的最主要原因。目前采用标准的化疗方案治疗,可使晚期转移性大肠癌的中位生存期提高【1J。自2008年1月至2010年12月我院共... 大肠癌是世界范围内最常见的恶性肿瘤之一,我国近年来发病率有升高趋势。局部复发和远处转移是大肠癌治疗失败的最主要原因。目前采用标准的化疗方案治疗,可使晚期转移性大肠癌的中位生存期提高【1J。自2008年1月至2010年12月我院共收治晚期肠癌36例,采用FOLFOX4方案治疗,取得了较好的疗效,现将护理体会报道如下。 展开更多
关键词 大肠癌:化疗护理 FOLFOX4方案
下载PDF
Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in China's Mainland 被引量:18
3
作者 Tao Suo Haile Mahteme Xin-Yu Qin 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第8期1071-1075,共5页
AIM:To investigate the current status of peritoneal carcinomatosis(PC) management,as well as the usage of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) in China's Mainland.METHODS... AIM:To investigate the current status of peritoneal carcinomatosis(PC) management,as well as the usage of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) in China's Mainland.METHODS:A potentially curative therapeutic strategy for selecting patients with PC,known as "Techniques",consists of CRS in combination with HIPEC.A systemic search of published works and clinical trials was performed.Additional papers were retrieved by crosschecking references and obtaining information from Chinese oncologists and relevant conferences.One hundred and one papers and one registered clinical trial on HIPEC were included.RESULTS:A literature review identified 86 hospitals in 25 out of all 31 areas of China's Mainland that perform HIPEC.The earliest report included in our survey was published in 1993.Different approaches to HIPEC have been utilized,i.e.palliative,prophylactic,and possiblycurative treatment.Only one center has consistently performed HIPEC according to the "Sugarbaker Protocol",which involves evaluating the extent of PC with peritoneal cancer index and the results of CRS with the completeness of cytoreduction.Positive preliminary results were reported:7 of 21 patients with PC survived,free of tumors,during an 8-43-mo follow-up period.Hyperthermic strategies that include HIPEC have been practiced for a long time in China's Mainland,whereas the "Sugarbaker Protocol/Techniques" has been only rarely implemented in China.The Peritoneal Surface Oncology Group International hosts a biannual workshop with the intent to train more specialists in this field and provide support for the construction of quality treatment centers,especially in developing countries like China,whose population is huge and has a dramatically increased incidence of cancer.CONCLUSION:To popularize Sugarbaker Protocol/Techniques in China's Mainland in PC management arising from gastric cancer or colorectal cancer will be the responsibility of the upcoming Chinese Peritoneal Surface Oncology Group. 展开更多
关键词 Peritoneal carcinomatosis HYPERTHERMIA Prophylactic strategy Sugarbaker Protocol/techniques China's Mainland
下载PDF
Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases 被引量:5
4
作者 Claudia Rubie Vilma Oliveira Frick +6 位作者 Pirus Ghadjar Mathias Wagner Christoph Justinger Stefan Graeber Jens Sperling Otto Kollmar Martin K Schilling 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第26期3109-3116,共8页
AIM: To evaluate the influence of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in liver metastases of stage IV colorectal cancer (CRC) patients.(/7 = 53) and in patients who did not receive FOLFOX ch... AIM: To evaluate the influence of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in liver metastases of stage IV colorectal cancer (CRC) patients.(/7 = 53) and in patients who did not receive FOLFOX chemotherapy prior to liver surgery (n = 29). RESULTS: Of the 53 patients who received FOLFOX, time to liver surgery was n〈 1 mo in 14 patients, 〈 1 year in 22 patients and 〉 1 year in 17 patients, respectively. In addition, we investigated the proliferation rate of CRC cells in liver metastases in the different patient groups. Both CCL20 and CCR6 mRNA and protein ex- pression levels were significantly increased in patients who received preoperative FOLFOX chemotherapy ~〈 12 mo before liver surgery (P 〈 0.001) in comparison to patients who did not undergo FOLFOX treatment. Further, proliferation of CRLM cells as measured by Ki-67 was increased in patients who underwent FOLFOX treat- ment. CCL20 and CCR6 expression levels were significantly increased in CRLM patients who had undergone preoperative FOLFOX chemotherapy. CONCLUSION: This chemokine/receptor up-regulation could lead to increased proliferation/migration through an autocrine mechanism which might be used by surviving metastatic cells to escape cell death caused by FOLFOX. 展开更多
关键词 FOLFOX chemotherapy CCL20/CCR6 expression Colorectal liver metastases Proliferation
下载PDF
Autologous cytokine-induced killer cells combined with chemotherapy in the treatment of advanced colorectal cancer: a randomized control study 被引量:1
5
作者 Cheng Du Zhaozhe Liu +3 位作者 Zhenyu Ding Fang Guo Dongchu Ma Xiaodong Xie 《The Chinese-German Journal of Clinical Oncology》 CAS 2013年第10期487-491,共5页
Objective:To evaluate the ef icacy of autologous cytokine-induced kil er (CIK) cells transfusion combined with chemotherapy in patients suf ered from advanced colorectal cancer. Methods: Sixty untreated patients w... Objective:To evaluate the ef icacy of autologous cytokine-induced kil er (CIK) cells transfusion combined with chemotherapy in patients suf ered from advanced colorectal cancer. Methods: Sixty untreated patients with advanced colorectal cancer were randomly divided into two groups. The 30 patients in the control group received chemotherapy with the regimen of xeloda plus oxiplatin (XELOX). The 30 patients in the trial group were treated with chemotherapy (XELOX) in combination with autologous CIK celltransfusion. T-lymphocyte subgroups were separated and measured by flow cytometry quality of life (QOL) was determined by EORTC QLQ-C30. The short-term curative ef ect was evaluated via imaging examina-tions. The patients’ median progression free survival time was estimated by Kaplan-Meier. Results:The T-lymphocyte im-mune activity was improved in patients received autologous CIK celltransfusion than those treated with chemotherapy alone. The subgroup of CD3+CD56+T lymphocyte was significantly increased (4.28 ± 0.45 vs 10.14 ± 1.02, P=0.01). Short-term ef icacy evaluation revealed that there was no significant dif erence in terms of objective response rate (ORR) between the two groups, but the disease control rate (DCR) was markedly increased (86.7%vs 56.7%, P=0.020) in the group treated by chemotherapy plus CIK cells compared to the group treated with chemotherapy alone. The progression free survival time was 8.64 months ( 95%CI 6.25-9.75 months) in control group and 10.15 months ( 95%CI 7.48-12.52 months) in trial group. Compared to patients in control group, the patients in trial group had significantly longer progression-free survival (P=0.046). The QOL assessment suggested the QOL in trial group was obviously improved than that in the control group. Compared with the control group, patients treated with autologous CIK celltransfusion scored more in the area of physical function and general health status, while the symptomatic scores in terms of pain, fatigue, nausea and vomiting and diarrhea were significantly reduced. Conclusion:Autologous CIK celltransfusion combined with chemotherapy can ef ectively enhance the immune activity of T-lymphocytes, prevent disease progression and improve the progression-free survival and QOL in patients with advanced colorectal cancer. 展开更多
关键词 colorectal cancer cytokine-induced kil er (CIK) adoptive immune celltherapy chemotherapy
下载PDF
Clinical Study of Combining Chemotherapy of Oxaliplatin or 5-Fluorouracil/Leucovorin with Hydroxycamptothecine for Advanced Colorectal Cancer 被引量:1
6
作者 Yuanjue Sun Hui Zhao Yaowu Guo Feng Lin Lina Tang Yang Yao 《Chinese Journal of Clinical Oncology》 CSCD 2009年第2期117-123,共7页
OBJECTIVE To estimate effects, survival rate after the short-time efficacy, side the treatment of combining chemotherapy of oxaliplatin or 5-fluorouracil/leucovorin with hydroxycamptothecine (HCPT) for the patients ... OBJECTIVE To estimate effects, survival rate after the short-time efficacy, side the treatment of combining chemotherapy of oxaliplatin or 5-fluorouracil/leucovorin with hydroxycamptothecine (HCPT) for the patients with advanced colorectal cancer. METHODS From January 2002 to November 2005, 59 patients with advanced colorectal cancer confirmed by pathology were enrolled into this study in the department of medical oncology, in the Sixth People's Hospital of Shanghai Jiaotong University, Shanghai. Patients' characteristics in two groups were similarly confirmed by statistic. All 37 patients in OH group received oxalip21atin (130 mg/m^2 d1) plus hydroxycamptothecine (6 mg/m d1-4), and all 22 patients in the HLF group received hydroxycamptothecine (6 mg/m^2 d1-4) plus leucovorin (300 mg d1-5) and 5-fluorouracil (0.375 g/m^2 d1-5). The regimens in both groups were 21-day cycle that was repeated three weeks. The side effects were evaluated. The efficacy was estimated after two cycles of chemotherapy for each patient. RESULTS The efficacy of the treatment in the OH group with 37 patients and in the HLF group with 22 patients was estimated. The overall response rate (CR + PR) was 32.4% in the OH group and 22.7% in the HLF group. There was no complete response (CR) and there was no statistical significantly difference (%2= 0.876, P = 0.704) in two groups. The 1-year survival rate was 30.98% in the OH group and 15.02% in the HLF group, and it had no significant difference between the two groups. The median PSF and OS were 5.83 months and 11.17 months in the OH group vs. 7.40 months and 10.48 months in the HLF group, and it had no significant differences between the two groups (P 〉 0.05). The major side effects of grade III and IV in the two groups were myelosuppression and gastrointestinal reactions. The statistically significant difference in side effects appeared in leukopenia (χ^2= 17.173, P = 0.001), nausea/vomiting (χ^2= 6.426, P = 0.039), diarrhea (χ^2= 16.245, P = 0.000) and peripheral neuropathy. CONCLUSION The efficacy was almost equal between the OH and the HLF groups, and the two regimens can be used as the second-line treatments for the patients with colorectal cancer. Leucopenia, nausea, diarrhea and peripheral neuropathy appeared more in OH group, and anemia and thrombocytopenia were almost equal between the OH and the HLF groups. 展开更多
关键词 OXALIPLATIN hydroxycamptothecine 5-FLUOROURACIL colorectal cancer.
下载PDF
Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases
7
作者 Ping Chen Bei Zhang +2 位作者 Guifang Guo Liangping Xia Huijuan Qiu 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第5期229-234,共6页
Objective: The combination of hepatic arterial chemotherapy(HAIC) and systemic chemotherapy(SYC) has potential effect on colorectal cancer(CRC) patients with unresectable hepatic metastasis. The aim of this retrospect... Objective: The combination of hepatic arterial chemotherapy(HAIC) and systemic chemotherapy(SYC) has potential effect on colorectal cancer(CRC) patients with unresectable hepatic metastasis. The aim of this retrospective study was to investigate the efficacy and safety of this combined therapeutic regimen on Chinese patients based on single institute experiences. Methods: All 54 patients of this retrospective analysis were diagnosed with CRC with unresectable liver metastasis and received combined HAIC and SYC. Among the patients, 23 of them received HAIC plus SYC when they developed liver metastases as first-line treatment(Group 1), and 31 patients received HAIC plus SYC as non-first-line treatment(Group 2). The different efficacy in two groups was analyzed by SPSS 19.0. Results: The overall response rate(ORR) were 52.2% and 25.8% respectively in Groups 1 and 2(P = 0.047), and the disease control rate(DCR) were 65.2% and 35.5% respectively in Groups 1 and 2(P = 0.031). The median progression-free survival(PFS) were 6.8 and 3.3 months(P = 0.002), the median hepatic progression-free survival(H-PFS) were 8.8 and 3.7 months(P = 0.001), and the median overall survival(OS) were 18.8 and 13.7 months(P = 0.121) in Groups 1 and 2, respectively. No fatal reaction was observed and no significant difference of adverse reaction was found in two groups. Grade 3/4 toxic effects included neutropenia(9.7% in Group 2 only), gastrointestinal reaction(8.7% in Group 1 and 6.5% in Group 2), stomatitis(6.5% in Group 2 only) and hyperbilirubinemia(4.3% in Group 1 only). Conclusion: HAIC combined with SYC showed promising efficacy and safe profiles on CRC patients with unresectable liver metastases. 展开更多
关键词 colorectal cancer (CRC) unresectable hepatic metastasis systemic chemotherapy (SYC) hepatic arterial che-motherapy (HAIC)
下载PDF
ERCC1 Asn118Asn polymorphism as predictor for cancer response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer
8
作者 Jun Liang Hongying Lv +2 位作者 Ruyong Yao Hua Liang Gang Wu 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第8期455-459,共5页
Objective: To assess whether the polymorphism of ERCC1 Asn118Asn (C → T) had effects on cancer response to chemotherapy and outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimen f... Objective: To assess whether the polymorphism of ERCC1 Asn118Asn (C → T) had effects on cancer response to chemotherapy and outcome in Chinese patients treated with oxaliplatin as first-line chemotherapy regimen for advanced colorectal cancer. Methods: ERCC1 Asn 118Asn polymorphism was analyzed in 99 patients with stages Ⅲ and Ⅳ advanced colorectal cancer treated with oxaliplatin-based chemotherapy, For all of the patients, ERCC1 Asnl18Asn genotype was analyzed for associations with treatment response and time to disease progress (TTP). Results: The allele frequencies of the ERCC1 gene codon 118 were C/C 50.51% (50/99), C/T 41.41% (41/99), T/T 8.08% (8/99), respectively. Patients with C/C genotype showed higher response rate than those with C/T + T/T (OR = 3.764, 95% CI: 1.310-10.813). The median TTP of all patients was 7 months (95% CI: 5.569--8.431). Patients with C/C genotype showed a median TTP of 10 months (95% CI: 8.924-11.076), which was longer than 5 months (95% CI: 4.424-5.576) in patients with C/T + T/T genotypes. Conclusion: Our results showed a link between ERCC1 Asn118Asn genetic polymorphism and cancer response to oxaliplatin-based chemotherapy and time to disease progress in Chinese patients with advanced colorectal cancer. ERCC1 Asn 118Asn genotyping may be of predictive benefit in selecting treatment regimen for advanced colorectal cancer. 展开更多
关键词 colorectal neoplasm alleles POLYMORPHISM excision repair cross-complementation group 1 (ERCC1) OXALIPLATIN
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部